OphthaliX to Acquire Improved Vision Systems

Can-Fite BioPharma announced Friday that subsidiary OpthaliX has signed a definitive agreement to acquire Israeli devicemaker Improved Vision Systems.

I.V.S. designs medical devices for the ophthalmology market. The company is developing an indoor eye tracking product, able to attach to any screen, that manipulates the image the user sees to compensate for specific clinical impairment; and a goggles-based mobile device that can generate high definition displays which are manipulated and moved via the device’s ability to trach each eye individually.

In addition, OpthaliX will continue to develop drug candidate CF101, a neuroprotective and anti-inflammatory drug for glaucoma treatment.

I.V.S. executive Ran Yam will be appointed OpthaliX CEO after initial closing. — Jason Scott